NCT04109729View on ClinicalTrials.gov

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

July 30, 2025

Study Completion Date

April 30, 2026

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Nivolumab

Nivolumab 480mg IV every 4 weeks for up to 2 years

DRUG

Radium-223

Radium-223 55 kilobecquerel (kBq)/kg IV q4 weeks for 6 cycles total

Trial Locations (1)

84112

Huntsman Cancer Institute at University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER